BioSpace News Archive

Phosplatin Therapeutics LLC , a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data from a Phase I Dose Escalation Study of its lead candidate PT-112, an immunogenic cell death (ICD) inducer, in patients with relapsed or refractory multiple myeloma will be presented at the 62nd American So

Click Therapeutics announced today that Solera Health, the premier platform for addressing chronic conditions, will add Clickotine®, a clinically validated, fully digital smoking cessation program, for members of Blue Shield of California. Clicko

– OXLUMO is the First Therapeutic Approved for the Treatment of PH1, and the Only Therapy Proven to Lower Harmful Oxalate Levels that Drive the Progression of PH1 Disease –

NeuPath Health Inc. (TSXV:NPTH) (formerly Klinik Health Ventures Corp.) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, today announced its financial and operating results for the three and nine months ended September 30, 2020.

GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors

Medable Inc. announced $91 million in new funding to accelerate the life sciences industry’s shift to digital and decentralized clinical trials.

Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease de

Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020. TNB-383B is a fully human bispecifi

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the pricing of its public offering of 7,500,000 ordinary shares at a public offering price of $10.00 per share.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its joint sponsorship with WPD Pharmaceuticals for the 2020 Society of NeuroOncology (SNO) Vir